[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3684 Introduced in House (IH)]

<DOC>






118th CONGRESS
  1st Session
                                H. R. 3684

  To direct the Secretary of Defense to establish a grant program for 
using psychedelic substances to treat certain conditions, and for other 
                               purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 25, 2023

  Mr. Crenshaw (for himself, Mr. Luttrell, Mr. Bergman, Ms. Mace, Mr. 
Gaetz, Ms. Ocasio-Cortez, Mr. Moskowitz, Mr. Zinke, Ms. Lee of Florida, 
Mr. Correa, and Mr. Van Orden) introduced the following bill; which was 
              referred to the Committee on Armed Services

_______________________________________________________________________

                                 A BILL


 
  To direct the Secretary of Defense to establish a grant program for 
using psychedelic substances to treat certain conditions, and for other 
                               purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Douglas `Mike' Day Psychedelic 
Therapy to Save Lives Act of 2023''.

SEC. 2. GRANT PROGRAM OF THE DEPARTMENT OF DEFENSE TO STUDY TREATMENT 
              OF CERTAIN CONDITIONS USING CERTAIN PSYCHEDELIC 
              SUBSTANCES.

    (a) Establishment.--Not later than 90 days after the date of 
enactment of this Act, the Secretary of Defense shall award grants to 
eligible entities to conduct research on the treatment of members of 
the Armed Forces serving on active duty with a covered condition using 
covered psychedelic substances. Not later than 60 days after the date 
of the enactment of this Act, the Secretary shall designate a lead 
administrator to carry out the grant program under this section.
    (b) Eligible Entities.--The Secretary may award a grant under this 
section to any of the following:
            (1) A department or agency of the Federal Government or a 
        State government.
            (2) An academic institution.
            (3) A nonprofit entity.
    (c) Use of Grant Funds.--A recipient of a grant awarded under this 
section may use the grant to--
            (1) conduct one or more phase two clinical trials for the 
        treatment of covered conditions that--
                    (A) include members of the Armed Forces serving on 
                active duty as participants in the clinical trial; and
                    (B) use individual or group therapy assisted by 
                covered psychedelic substances; or
            (2) train practitioners to provide treatment to members of 
        the Armed Forces serving on active duty for covered conditions 
        using covered psychedelic substances.
    (d) Participation in Clinical Trials.--The Secretary shall 
authorize any member of the Armed Forces diagnosed with a covered 
condition to participate in a clinical trial that is conducted using a 
grant awarded under this section or funds provided under subsection (e) 
and is authorized pursuant to section 505 of the Federal Food, Drug, 
and Cosmetic Act (21 U.S.C. 355), without regard to--
            (1) whether the clinical trial involves a substance 
        included in the schedule under section 202 of the Controlled 
        Substances Act (21 U.S.C. 812); or
            (2) section 912a of title 10, United States Code (article 
        112a of the Uniform Code of Military Justice).
    (e) Additional Authority.--In addition to awarding grants under 
this section, the Secretary shall provide funds for a clinical research 
trial using covered psychedelic substances that is authorized pursuant 
to section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
355) and includes members of the Armed Forces as participants in the 
trial.
    (f) Report Required.--Not later than 180 days after the date of the 
enactment of this Act, and every 180 days thereafter, the Secretary 
shall submit to the Committees on Armed Services of the House of 
Representatives and the Senate a report on grants awarded under this 
section, including the following:
            (1) Identification of clinics designated to host activities 
        under such a grant.
            (2) A description of entities to whom the Secretary has 
        awarded such a grant.
            (3) The number of members of the Armed Forces who 
        participated in a clinical trial described in subsection (d).
            (4) Information on the findings of such clinical trials.
    (g) Authorization of Appropriations.--There is authorized to be 
appropriated to the Secretary to carry out this section $15,000,000 for 
each of fiscal years 2024 through 2028.
    (h) Definitions.--In this section:
            (1) The term ``covered condition'' means any of the 
        following:
                    (A) Post-traumatic stress.
                    (B) Traumatic brain injury.
                    (C) Chronic traumatic encephalopathy
            (2) The term ``covered psychedelic substances'' means any 
        of the following:
                    (A) 3,4-Methylenedioxy-methamphetamine (commonly 
                known as ``MDMA'').
                    (B) Psilocybin.
                    (C) Ibogaine.
                    (D) 5-Methoxy-N,N-dimethyltryptamine (commonly 
                known as ``5-MeO-DMT'').
            (3) The term ``State'' has the meaning given such term in 
        section 901 of title 32, United States Code.
                                 <all>